Risk of lymph node metastasis in mixed-type early gastric cancer determined by the extent of the poorly differentiated component

Chung-Su Hwang, Sangjeong Ahn, Bong-Eun Lee, So-Jeong Lee, Ahrong Kim, Chang In Choi, Dae Hwan Kim, Tae-Yong Jeon, Gwang Ha Kim, Geum Am Song, Do Youn Park

The authors declare no conflict of interests.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Do Youn Park, MD, PhD, Department of Pathology, Pusan National University Hospital and Pusan National University School of Medicine, 1-10 Ami-Dong, Seo-Gu, Busan 602-739, South Korea. pdy220@pusan.ac.kr

Received: October 20, 2015
Peer-review started: October 22, 2015
First decision: November 27, 2015
Revised: December 2, 2015
Accepted: January 17, 2016
Article in press: January 18, 2016
Published online: April 21, 2016

Abstract

AIM: To predict the rate of lymph node (LN) metastasis in diffuse- and mixed-type early gastric cancers (EGC) for guidelines of the treatment.

METHODS: We reviewed 550 cases of EGC with
INTRODUCTION

Endoscopic submucosal dissection (ESD), a recently developed technique, is a widely accepted treatment modality for early gastric cancer (EGC), including for diffuse (undifferentiated) type EGC within the expanded criteria (mucosal cancer measuring less than 2 cm without ulceration and lymphovascular tumour emboli). Large datasets indicate almost no risk of lymph node (LN) metastasis in diffuse type EGCs.

A considerable proportion of gastric adenocarcinomas show a mixed composition with both intestinal and diffuse histological components. No consensus has been established regarding the management of mixed-type histology, i.e., varying proportions of diffuse and intestinal components in the tumour.

Generally, gastric adenocarcinoma can be subclassified into intestinal (differentiated) and diffuse (undifferentiated) types based on gland formation. According to Japanese guidelines, diffuse components are further subdivided into signet ring cell carcinoma and poorly differentiated carcinoma. These guidelines refer to mixed-type EGCS by their predominant histological component, whether intestinal or diffuse.

There are several reports on the management and outcomes of mixed-type EGCS. Takizawa et al. reported that mixed-predominantly diffuse type showed significant LN metastasis and suggested that their treatment be similar to that of diffuse-type EGCs. Hanaoka et al. reported that the predominantly undifferentiated mixed-type tumours showed considerably higher LN metastasis than other types of submucosal invasive EGCS. Furthermore, Min et al. reported that mixed intestinal- and diffuse-type EGCS could be managed with ESD under the expanded criteria.

We investigated 550 cases of diffuse- and mixed-type EGCS to determine which components of the diffuse subtypes (signet ring cell or poorly differentiated carcinoma) are more closely associated with LN metastasis, providing evidence to establish a consensus for the management of diffuse- and mixed-type EGCS with ESD.

MATERIALS AND METHODS

Patient selection and clinicopathological evaluation

We retrieved early gastric cancer cases that involved gastrectomies with LN dissection at the Pusan National University Hospital treated between 2008 and 2013, and selected 550 cases of EGC with diffuse- and mixed-type histology based on the Japanese classification of gastric cancer. Cases involving
Table 1  Clinicopathological factors and lymph node metastasis in early gastric cancers \( n \) (%)

| Total   | Negative \( (n = 479) \) | Positive \( (n = 71) \) | \( P \) value |
|---------|--------------------------|--------------------------|-------------|
| Sex     |                          |                          | 0.950       |
| Male    | 304                      | 265 (87.2)               | 39 (12.8)   |
| Female  | 246                      | 214 (87.0)               | 32 (13.0)   |
| Age (yr) | 550                  | 54.5 \( \pm \) 0.7       | 55.3 \( \pm \) 2.5 | 0.686   |
| Site\( ^1 \) |                  |                          | 0.059       |
| Upper   | 129                     | 120 (93.0)               | 9 (7.0)     |
| Middle  | 252                     | 217 (86.1)               | 35 (13.9)   |
| Lower   | 169                     | 142 (84.0)               | 27 (16.0)   |
| Gross type |                   |                          | 0.030       |
| Elevated | 59                     | 45 (76.3)                | 14 (23.7)   |
| Flat    | 51                      | 46 (90.2)                | 6 (9.8)     |
| Depressed | 440                      | 388 (88.2)               | 52 (11.8)   |
| Ulceration |                   |                          | 0.640       |
| Absent  | 445                     | 389 (87.4)               | 56 (12.6)   |
| Present | 105                     | 90 (85.7)                | 15 (14.3)   |
| Tumour size (cm)\( ^2 \) | |            | 0.0001      |
| \( \leq \) 1 | 40                      | 39 (97.5)                | 1 (2.5)     |
| \( \leq \) 2 | 126                     | 120 (95.2)               | 6 (4.8)     |
| \( \leq \) 3 | 141                     | 125 (88.7)               | 16 (11.3)   |
| \( > \) 3 | 243                     | 195 (80.2)               | 48 (19.8)   |
| Depth of invasion\( ^3 \) | |            | 0.0001      |
| Mucosa  | 288                     | 273 (94.8)               | 15 (5.2)    |
| M2      | 50                      | 49 (98.0)                | 1 (2.0)     |
| M3      | 238                     | 224 (94.1)               | 14 (5.9)    |
| Submucosa | 262                  | 206 (78.6)               | 56 (21.4)   |
| SM1     | 33                      | 30 (90.9)                | 3 (9.1)     |
| SM2     | 67                      | 55 (82.1)                | 12 (17.9)   |
| SM3     | 162                     | 121 (74.7)               | 41 (25.3)   |
| Depth (\( \mu \)m) | 262                  | 1734 ± 89.4             | 207 ± 130.3 | 0.153   |
| Perineural invasion | |            | 0.0001      |
| Absent  | 495                     | 442 (89.3)               | 53 (10.7)   |
| Present | 55                      | 37 (67.3)                | 18 (32.7)   |
| LV invasion |           |                          | 0.0001      |
| Absent  | 518                     | 464 (89.6)               | 54 (10.4)   |
| Present | 32                      | 15 (46.9)                | 17 (53.1)   |

\( ^1 \)Between upper vs middle+lower; \( ^2 \)Between \( \leq \) 2 cm vs \( > \) 2 cm; \( ^3 \)Between M vs SM. LV: Lymphovascular; M2: Lamina propria invasion; M3: Muscularis mucosae invasion without penetration; SM1: Upper third; SM2: Middle third; SM3: Lower third.

RESULTS

Clinicopathological characteristics relevant to LN metastasis

Clinicopathological characteristics as a status of LN metastasis are listed in Table 1. Of 550 cases, 71 (12.9\%) showed LN metastasis [15/288 mucosal EGCS (5.2\%) and 56/262 submucosal EGCS (21.4\%)]. Increased tumour size, gross type (elevated), depth of invasion, and perineural and lymphovascular invasion were associated with LN metastasis. Furthermore, we investigated the independent predictive risk factors for LN metastasis using binary logistic regression analysis (Supplemental Table 1). Tumour size \( (P = 0.001) \), depth of invasion \( (P < 0.0001) \), and lymphovascular invasion \( (P = 0.001) \) were independent predictive risk measured directly using a micrometre and was defined as the distance from the lowest point of the muscularis mucosa (or surface of ulceration) to the point of deepest tumour penetration. The Institutional Review Board at the Hospital approved this study.

Histopathologic evaluation with regard to histological subtypes

We reviewed all slides and estimated the proportions of each tumour component. Diffuse components (undifferentiated) were further subdivided into signet ring cell (sig) or poorly differentiated (por) types. Subclassification was according to the most prevalent component, applying the 50\% criterion, as follows: pure diffuse type, mixed-predominantly diffuse type (diffuse \( \geq \) intestinal type), mixed-predominantly intestinal type (intestinal type \( > \) diffuse), and mixed diffuse = intestinal type\( ^{[7]} \). We calculated the extents of the respective components using the following formula: extent of respective component (cm) = dimension of tumour (cm) \( \times \) estimated percentage of the respective component/100.

Statistical analysis

Statistical calculations were performed using SPSS for Windows (version 12K, Chicago, IL, United States). To identify the predictive risk factors for LN metastasis, the data were statistically analysed using the chi-squared test and an unpaired Student's \( t \) test. The independent factors for LN metastasis in diffuse- and mixed-type EGCS were analysed by binary logistic regression analysis (backward, stepwise). The ability of histological component extent to predict LN metastasis was assessed using receiver operating characteristic (ROC) curve analysis. The total areas under the ROC curves ranged from 0.5 to 1.0, with 1.0 indicating perfect predictive value and 0.5 indicating random chance. A pairwise comparison of the areas under the ROC curve was subsequently performed to assess the predictive value of each histological component. A \( P < 0.05 \) was deemed statistically significant.

preoperative chemotherapy or radiotherapy or multiple gastric cancers were excluded. Pathological reports and electronic medical records were reviewed, for attributes, including sex, age, site, gross type, presence of ulceration, tumour size, depth of invasion, perineural invasion, lymphovascular invasion, and LN metastasis status. Lesions were classified into the following three groups according to gross type: elevated type (I, IIa, IIIa + IIIb, and IIa + IIc), flat type (IIb, IIb + IIa, and IIb + IIc), and depressed type (IIc, IIc + IIb, IIc + III, IIc + IIa, and III). Ulceration was defined as a deformity of the muscularis propria or fibrosis in the submucosal layer. Intramucosal carcinoma was categorized as M2 (lamina propria invasion) or M3 (muscularis mucosae invasion without penetration). Submucosal invasion was graded as SM1 (upper third), SM2 (middle third), or SM3 (lower third). The depth of submucosal invasion was
factors for LN metastasis in diffuse- and mixed-type EGCs. In our dataset, there were 80 cases of mucosal EGCs less than 2.0 cm in size and without ulceration; among them, only 1 case showed LN metastasis (Table 2). Hence, only 1 case within ESD eligibility criteria showed LN metastasis in this study.

**Histological subtypes and LN metastasis**
Of 550 cases, 302 were diffuse-type and 248 were mixed-type EGCs (Figure 1; Supplemental Tables 2 and 3). Furthermore, 28 of the 302 diffuse-type (9.3%) and 43 of the 248 mixed-type EGCs (21.0%) showed LN metastasis. The clinicopathological features associated with LN metastasis in each type were similar to those associated with LN metastasis when diffuse and mixed types were considered together, e.g., tumour size, depth of invasion, and perineural and lymphovascular tumour invasion. Depth of submucosal invasion was significantly associated with LN metastasis in mixed-type ($P = 0.044$), but not in diffuse-type EGCs ($P = 0.905$).

Of 248 mixed-type EGCs, 163 were mixed-predominantly diffuse type, 82 were mixed-predominantly intestinal type, and 3 were mixed diffuse = intestinal type (Table 3). Interestingly, LN metastasis was more frequent in the mixed-predominantly diffuse type (33/163, 20.2%) than in either the pure diffuse type (28/302, 9.3%) or the mixed-predominantly intestinal histological type (10/82, 12.2%; $P = 0.003$).

**Quantitative impact of histopathological subtypes on LN metastasis**
We measured the extent of the individual components to determine the quantitative power of each to predict LN metastasis. The total tumour size and the

| Mucosal carcinoma | Submucosal carcinoma |
|-------------------|----------------------|
|                   | No ulcer | Ulcer | SM1 | SM2 | SM3 | Any size |
| Diffuse (n = 302) |          |       |     |     |     |          |
| ≤ 2 cm            | 1/61 (1.6) | 5/86 (5.8) | 2/22 (9.0) | 1/19 (5.3) | 0/12 (0) | 2/7 (28.6) | 6/32 (18.8) | 11/63 (17.5) |
| > 2 cm            | 0/19 (0)  | 5/64 (7.8) | 0/4 (0)  | 1/10 (10) | 0/6 (0)  | 1/8 (12.5) | 6/35 (17.1) | 30/99 (30.3) |
| Mixed (n = 248)   |          |       |     |     |     |          |
| ≤ 2 cm            | 0/10 (0)  | 10/150 (6.7) | 2/26 (7.7) | 2/29 (6.9) | 0/18 (0) | 3/15 (20.0) | 12/67 (17.9) | 41/162 (25.3) |
| > 2 cm            | 1/80 (1.3) | 10/150 (6.7) | 2/26 (7.7) | 2/29 (6.9) | 0/18 (0) | 3/15 (20.0) | 12/67 (17.9) | 41/162 (25.3) |

SM1: Upper third; SM2: Middle third; SM3: Lower third.

---

### Table 2 Lymph node metastasis according to depth of invasion, ulceration, and tumour size ($n$ (%))

Table 2

| Submucosal carcinoma |
|----------------------|
| SM1 | SM2 | SM3 |
| Any size |
| ≤ 3 cm | > 3 cm | ≤ 3 cm | > 3 cm | Any size |
| 6/32 (18.8) | 11/63 (17.5) | 6/35 (17.1) | 30/99 (30.3) | 12/67 (17.9) | 41/162 (25.3) |

A: Mixed-type gastric carcinoma showing moderately differentiated tubular adenocarcinoma, intestinal type (upper left and right) and poorly differentiated adenocarcinoma (lower left); B: High magnification view of poorly differentiated lesion ($\times 400$); C: Mixed-type gastric carcinoma showing moderately differentiated tubular adenocarcinoma, intestinal type (right) and signet ring cell carcinoma (left); D: High magnification view of signet ring cell carcinoma lesion ($\times 400$).
within the expanded criteria showed no LN metastasis, this was based on the risk of LN metastasis without ulceration or lymphovascular tumour emboli; to include mucosal lesions measuring less than 2.0 cm type EGCs eligible for endoscopic resection expanded with the development of ESD, the criteria for diffuse- and mixed-type early gastric cancers.

DISCUSSION

With the development of ESD, the criteria for diffuse-type EGCs eligible for endoscopic resection expanded to include mucosal lesions measuring less than 2.0 cm without ulceration or lymphovascular tumour emboli; this was based on the risk of LN metastasis. Hirasawa et al. reported that 310 diffuse-type EGCs within the expanded criteria showed no LN metastasis, in contrast to an earlier report by Gotoda et al.[13]. Shim and Lee summarized previously published datasets describing the risks of LN metastasis for diffuse-type EGCs that meet the proposed criteria[3], concluding that these expanded criteria for ESD of diffuse type EGC are feasible with regard to efficacy and safety.

Consistent with other reports that reported low or no LN metastasis rates, we noted only one such metastasis among cases within the established expanded ESD criteria (1/80, 1.3%). We also identified various clinicopathological factors associated with LN metastasis, including increased size, gross type (elevated), depth of invasion, and perineural and lymphovascular invasion; this was consistent with previously published data[14,15]. Taken together, the expanded criteria for diffuse-type EGC can be used to determine the primary option for treatment. Mixed-predominantly diffuse EGCs showed a higher frequency of LN metastasis (20.2%) than either the pure diffuse type (9.3%) or the mixed-predominantly intestinal type (12.2%), in accordance with previous reports[7,8], suggesting that mixed-predominantly diffuse EGC should be more stringently managed than pure diffuse-type EGC.

We further sub-categorized diffuse histological components into signet ring cell and poorly differentiated carcinoma, and evaluated the impact of each component on LN metastasis. Interestingly, we identified an increase in the extent of the total diffuse component - especially the poorly differentiated

![Figure 2](image-url)
component - was associated with LN metastasis. There was no such association between the extents of signet ring cell components or intestinal components with LN metastasis. Furthermore, ROC curve analysis of mixed-type EGCs showed that the total tumour size along with the extents of the diffuse and poorly differentiated components affected LN metastasis with statistical significance, while the extent of the signet ring cell component did not (Figure 2).

Many studies reported favourable outcomes of early signet ring cell carcinoma and recommended endoscopic resection as the primary treatment option, which is not the case for poorly differentiated carcinoma\[16-18\]. Ha et al\[17\] demonstrated that signet ring cell carcinoma within the expanded criteria showed no LN metastasis and favourable outcomes compared to undifferentiated carcinoma. Kim et al\[18\] reported that signet ring cell carcinoma had a lower rate of LN metastasis compared to poorly differentiated or tubular adenocarcinoma of the submucosal type. However, none of aforementioned studies demonstrated the association of signet ring cell carcinoma in mixed-type EGCs with LN metastasis. This study demonstrates that a larger, poorly differentiated histological component was associated with LN metastasis, whereas a larger signet ring cell component was not.

There are many limitations and possible errors in our method of measuring the exact size of the lesions. We measured the extent of each component by multiplying the percentage of each component with the largest diameter of the lesion. Although this method is not perfect, we believed that it would be sufficiently indicative of the role of each component.

In conclusion, our results support the use of the extended criteria for the therapeutic use of ESD in cases of diffuse-type EGCs, and we recommend careful identification and quantitative evaluation of each tumour component in mixed-type EGC specimens obtained by endoscopic resection.

**ACKNOWLEDGMENTS**

This study was presented in part at the 2015 USCAP meeting (Boston, MA, United States).

**REFERENCES**

1 Gotoda T, Yamamoto H, Soetikno RM. Endoscopic submucosal dissection of early gastric cancer. J Gastroenterol 2006; 41: 929-942 [PMID: 17096062 DOI: 10.1007/s00535-006-1954-3]
2 Gotoda T. Endoscopic resection of early gastric cancer: the Japanese perspective. Curr Opin Gastroenterol 2006; 22: 561-569 [PMID: 16891890 DOI: 10.1097/01.mog.0000239873.06243.00]
3 Shim CN, Lee SK. Endoscopic submucosal dissection for undifferentiated-type early gastric cancer: do we have enough data to support this? World J Gastroenterol 2014; 20: 3938-3949 [PMID: 24744583 DOI: 10.3748/wjg.v20.i14.393]
4 Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49 [PMID: 14320675]
5 Nakamura K, Sugano H, Takagi K. Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances. Gan 1968; 59: 251-258 [PMID: 5726267]
6 Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14: 101-112 [PMID: 21573743 DOI: 10.1007/s10120-011-0041-5]
7 Takizawa K, Ono H, Kakinuma N, Tanaka M, Hussuie N, Matsubayashi H, Yamauchi Y, Bando E, Terashima M, Kusakari K, Nakajima T. Risk of lymph node metastases from intramucosal gastric cancer in relation to histological types: how to manage the mixed histological type for endoscopic submucosal dissection. Gastric Cancer 2013; 16: 531-536 [PMID: 23192620 DOI: 10.1007/s10120-012-0220-z]
8 Hanako K, Tanabe S, Mikami T, Okayasu I, Saigenji K. Mixed-histologic-type submucosal invasive gastric cancer as a risk factor for lymph node metastasis: feasibility of endoscopic submucosal dissection. Endoscopy 2009; 41: 427-432 [PMID: 19418397 DOI: 10.1055/s-0029-1214495]
9 Min BH, Kim KM, Park CK, Lee JH, Rhee PL, Rhee JC, Kim JJ. Outcomes of endoscopic submucosal dissection for differentiated-type early gastric cancer with histological heterogeneity. Gastric Cancer

**COMMENTS**

**Background**

A considerable proportion of gastric adenocarcinomas show a mixed composition with both intestinal and diffuse histological components. No consensus has been established regarding the management of mixed-type histology.

**Research frontiers**

The authors investigated which components of the diffuse subtypes (signet ring cell or poorly differentiated carcinoma) are more closely associated with lymph node (LN) metastasis, providing evidence to establish a consensus for the management of diffuse- and mixed-type early gastric cancers (EGCs) with endoscopic submucosal dissection (ESD).

**Innovations and breakthrough**

This study consolidates correlations between clinicopathological characteristics of early gastric cancer and the risk of LN metastasis, which is important to select patients that will benefit from endoscopic submucosal dissection. This paper also shows that the amount of poorly differentiated tumour cells within mixed type early gastric cancer is correlated with the highest risk of LN metastasis.

**Applications**

The results of the present study support the use of the extended criteria for the therapeutic use of ESD in cases of diffuse-type EGCs, recommending careful identification and quantitative evaluation of each tumour component in mixed-type EGC specimens obtained by endoscopic resection.

**Terminology**

Gastric adenocarcinoma can be subclassified into intestinal (differentiated) and diffuse (undifferentiated) types based on gland formation. Diffuse components are further subdivided into signet ring cell carcinoma and poorly differentiated carcinoma. In practice, mixed-type EGCs, consisted of intestinal and diffuse type, are frequently encountered. The expanded criteria for ESD include diffuse (undifferentiated) mucosal EGC measuring less than 2 cm without ulceration and lymphovascular tumour emboli.

**Peer-review**

This paper shows that the amount of poorly differentiated tumour cells within mixed type early gastric cancer is correlated with the risk of LN metastasis. They emphasize the need for diligent histological characterization of patient specimens as conclusion. Their findings are interesting and useful for the future treatment of early gastric cancer.

**Hwang CS et al. Lymph node metastasis in diffuse EGC**
Hwang CS et al. Lymph node metastasis in diffuse EGC

2015; 18: 618-626 [PMID: 24801199 DOI: 10.1007/s10120-014-0378-7]

10 Komatsu S, Ichikawa D, Miyamae M, Shimizu H, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Kishimoto M, Otsuji E. Histological mixed-type as an independent prognostic factor in stage I gastric carcinoma. *World J Gastroenterol* 2015; 21: 549-555 [PMID: 25593472 DOI: 10.3748/wjg.v21.i2.549]

11 Miyamae M, Komatsu S, Ichikawa D, Kosuga T, Kubota T, Okamoto K, Konishi H, Shiozaki A, Fujiwara H, Kishimoto M, Otsuji E. Histological mixed-type as an independent risk factor for nodal metastasis in submucosal gastric cancer. *Tumour Biol* 2015; Epub ahead of print [PMID: 26242270 DOI: 10.1007/s13277-015-3864-6]

12 Hirasawa T, Gotoda T, Miyata S, Kato Y, Shimoda T, Taniguchi H, Fujisaki J, Sano T, Yamaguchi T. Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. *Gastric Cancer* 2009; 12: 148-152 [PMID: 19890694 DOI: 10.1007/s10120-009-0515-x]

13 Gotoda T, Yanagisawa A, Sasaki M, Ono H, Nakanishi Y, Shimoda T, Kato Y. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. *Gastric Cancer* 2000; 3: 219-225 [PMID: 11984739]

14 Son HJ, Song SY, Kim S, Noh JH, Sohn TS, Kim DS, Rhee JC. Characteristics of submucosal gastric carcinoma with lymph node metastatic disease. *Histopathology* 2005; 46: 158-165 [PMID: 15693888 DOI: 10.1111/j.1365-2559.2005.02049.x]

15 Son HJ, Myung W, Yoo HS, Park SH, Song SY, Kwon YD, Rhee JC. Prognostic indicators of gastric carcinoma confined to the muscularis propria. *Histopathology* 2007; 51: 105-110 [PMID: 17593085 DOI: 10.1111/j.1365-2559.2007.02725.x]

16 Hyung WJ, Noh SH, Lee JH, Huh JJ, Lah KH, Choi SH, Min JS. Early gastric carcinoma with signet ring cell histology. *Cancer* 2002; 94: 78-83 [PMID: 11815962]

17 Ha TK, An JY, Yoon HK, Noh JH, Sohn TS, Kim S. Indication for endoscopic mucosal resection in early signet ring cell gastric cancer. *Ann Surg Oncol* 2008; 15: 508-513 [PMID: 18071825 DOI: 10.1245/s10434-007-9660-9]

18 Kim BS, Oh ST, Yook JH, Kim BS. Signet ring cell type and other histologic types: differing clinical course and prognosis in T1 gastric cancer. *Surgery* 2014; 155: 1030-1035 [PMID: 24792508 DOI: 10.1016/j.surg.2013.08.016]

P- Reviewer: Ando T, Caboclo JL, Wang YH
S- Editor: Gong ZM  L- Editor: A  E- Editor: Liu XM
